Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna is dialing back its plans for new vaccines, shelving several key projects as it grapples with a sharp slowdown in ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...